SKF-107260

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameSKF-107260
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonistsIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3Integrin alpha-IIb/beta-3
Therapy Area/IndicationsThrombosisMyocardial Ischemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsThrombosisMyocardial Ischemia

Other Information

ATC CodeN/A
Related LinksN/A